Fort Washington Investment Advisors Inc. OH Acquires 234 Shares of Stryker Co. (NYSE:SYK)

Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Stryker Co. (NYSE:SYK) by 4.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,710 shares of the medical technology company’s stock after buying an additional 234 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Stryker were worth $2,126,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the fourth quarter worth approximately $25,000. Capital A Wealth Management LLC bought a new position in Stryker in the fourth quarter worth approximately $26,000. Rakuten Securities Inc. grew its stake in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new position in Stryker in the fourth quarter worth approximately $30,000. Finally, BankPlus Trust Department bought a new position in Stryker in the fourth quarter worth approximately $33,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.9%

Stryker stock opened at $377.01 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market capitalization of $143.90 billion, a price-to-earnings ratio of 48.58, a PEG ratio of 2.93 and a beta of 0.91. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The business has a fifty day moving average price of $372.73 and a 200-day moving average price of $375.83.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.50 EPS. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio is currently 45.41%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday. The Goldman Sachs Group set a $422.00 price objective on Stryker in a research note on Tuesday, March 4th. BTIG Research set a $403.00 target price on Stryker and gave the company a “buy” rating in a research report on Monday, April 14th. Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Finally, Roth Mkm lifted their price target on Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $427.30.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.